X
[{"orgOrder":0,"company":"Eledon Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eledon Health Commence Human Trials Evaluate AT-1501 in Kidney Transplantation","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2021","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II"},{"orgOrder":0,"company":"Eledon Pharmaceuticals","sponsor":"CareDx","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"CareDx and Eledon Pharmaceuticals Announce Collaborative Research Agreement","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2021","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Eledon Pharmaceuticals","sponsor":"CareDx","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eledon Pharmaceuticals CEO David-Alexandre C. Gros, M.D., to Present at CareDx Virtual Transplant Innovation Day during ASN Kidney Week 2021","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2021","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I"},{"orgOrder":0,"company":"Eledon Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eledon Pharmaceuticals Announces First Patient Dosed in Phase 2a Trial Evaluating Tegoprubart in IgA Nephropathy","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase II"},{"orgOrder":0,"company":"Eledon Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eledon Announces Positive Topline Results from Phase 2a Trial of Tegoprubart Demonstrating Safety, Target Engagement, and Biomarker Response in Patients Living with Amyotrophic Lateral Sclerosis","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II"},{"orgOrder":0,"company":"Eledon Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eledon Pharmaceuticals Announces Orphan Drug Designation Granted to Tegoprubart for the Prevention of Allograft Rejection in Pancreatic Islet Cell Transplantation","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase II"},{"orgOrder":0,"company":"Eledon Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eledon Pharmaceuticals Receives FDA Clearance of IND Application to Evaluate Tegoprubart for the Prevention of Rejection in Kidney Transplant Recipients","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2022","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Eledon Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eledon Pharmaceuticals Receives FDA Clearance of IND Application to Evaluate Tegoprubart in IgA Nephropathy","therapeuticArea":"Nephrology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","url1":"","url2":"","graph1":"Nephrology","graph2":"IND Enabling"},{"orgOrder":0,"company":"Eledon Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eledon Pharmaceuticals Announces Upcoming Presentations at ASN\u2019s Kidney Week 2022 and NEALS","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase II"},{"orgOrder":0,"company":"Eledon Pharmaceuticals","sponsor":"eGenesis","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"eGenesis and Eledon Pharmaceuticals Announce Collaboration for Use of Tegoprubart in Preclinical Xenotransplantation Studies","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical"},{"orgOrder":0,"company":"Eledon Pharmaceuticals","sponsor":"BVF Partners","pharmaFlowCategory":"D","amount":"$185.0 million","upfrontCash":"$35.0 million","newsHeadline":"Eledon Pharmaceuticals Announces up to $185 Million Financing to Advance Tegoprubart Kidney Transplantation Clinical Trials","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2023","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II"},{"orgOrder":0,"company":"Eledon Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eledon Pharmaceuticals Announces First Participant Dosed in Phase 2 BESTOW Trial Evaluating Tegoprubart for the Prevention of Rejection in Kidney Transplantation","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2023","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II"},{"orgOrder":0,"company":"Eledon Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eledon Pharmaceuticals Announces 12th Participant Enrolled in Phase 2 BESTOW Trial Evaluating Tegoprubart for the Prevention of Organ Rejection","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2024","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II"}]
Find Clinical Drug Pipeline Developments & Deals by Eledon Pharmaceuticals
Filters
Companies By Therapeutic Area
Details:
AT-1501 (tegoprubart) is an experimental humanized monoclonal antibody that inhibits CD40L. It is being evaluated for the treatment of Organ Rejection.
Lead Product(s):
Tegoprubart
Therapeutic Area: Immunology Product Name: AT-1501
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not ApplicableUpfront Cash: Not Applicable
Deal Type: Not ApplicableMarch 25, 2024
Details:
AT-1501 (tegoprubart) is an investigational, humanized IgG1 anti-CD40L antibody with high affinity for the CD40 ligand, which is investigated for the treatment of prevention of rejection in kidney transplantation.
Lead Product(s):
Tegoprubart
Therapeutic Area: Immunology Product Name: AT-1501
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not ApplicableUpfront Cash: Not Applicable
Deal Type: Not ApplicableSeptember 05, 2023
Details:
The Company intends to use the net proceeds to fund the clinical development of its lead asset AT-1501 (tegoprubart), an anti-CD40L antibody with high affinity for CD40 Ligand.
Lead Product(s):
Tegoprubart
Therapeutic Area: Neurology Product Name: AT-1501
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator:
BVF Partners
Deal Size: $185.0 millionUpfront Cash: $35.0 million
Deal Type: Private PlacementMay 01, 2023
Details:
AT-1501 (tegoprubart) is an investigational, humanized IgG1 anti-CD40L antibody with high affinity for the CD40 ligand. CD40L plays a pivotal role in immune system activation by mediating both antibody and cellular immune responses.
Lead Product(s):
Tegoprubart
Therapeutic Area: Immunology Product Name: AT-1501
Highest Development Status: Preclinical Product Type: Large molecule
Recipient:
eGenesis
Deal Size: UndisclosedUpfront Cash: Undisclosed
Deal Type: CollaborationJanuary 09, 2023
Details:
Tegoprubart (AT-1501) is a humanized IgG1 anti-CD40L antibody with high affinity for CD40L (also called CD154), a well-validated biological target with broad therapeutic potential. It was built around safety and engineered to maximize efficacy and half life.
Lead Product(s):
Tegoprubart
Therapeutic Area: Nephrology Product Name: AT-1501
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not ApplicableUpfront Cash: Not Applicable
Deal Type: Not ApplicableOctober 24, 2022
Details:
The study will evaluate the safety and efficacy of AT-1501 (tegoprubart), with the primary endpoint being change from baseline in urine protein (assessed as urine protein to creatinine ratio) after 24 weeks of therapy.
Lead Product(s):
Tegoprubart
Therapeutic Area: Nephrology Product Name: AT-1501
Highest Development Status: IND Enabling Product Type: Large molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not ApplicableUpfront Cash: Not Applicable
Deal Type: Not ApplicableSeptember 06, 2022
Details:
Tegoprubart (formerly AT-1501),an anti-CD40L antibody with high affinity for CD40 Ligand, a well-validated biological target with broad therapeutic potential, for the prevention of organ rejection in patients receiving a kidney transplant.
Lead Product(s):
Tegoprubart
Therapeutic Area: Immunology Product Name: AT-1501
Highest Development Status: Phase I/ Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not ApplicableUpfront Cash: Not Applicable
Deal Type: Not ApplicableAugust 01, 2022
Details:
AT-1501 (tegoprubart), an anti-CD40L antibody with high affinity for CD40 Ligand, a well-validated biological target with broad therapeutic potential for the prevention of allograft rejection in pancreatic islet cell transplantation.
Lead Product(s):
Tegoprubart
Therapeutic Area: Endocrinology Product Name: AT-1501
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not ApplicableUpfront Cash: Not Applicable
Deal Type: Not ApplicableJune 09, 2022
Details:
AT-1501 (Tegoprubart) is an investigational humanized monoclonal antibody that inhibits CD40 Ligand (CD40L), a membrane protein linked to increased peripheral immune responses and neuroinflammation in ALS.
Lead Product(s):
Tegoprubart
Therapeutic Area: Neurology Product Name: AT-1501
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not ApplicableUpfront Cash: Not Applicable
Deal Type: Not ApplicableMay 31, 2022
Details:
AT-1501 (tegoprubart), is a humanized IgG1 anti-CD40L antibody with high affinity for CD40L (also called CD154), a well-validated biological target with broad therapeutic potential.
Lead Product(s):
Tegoprubart
Therapeutic Area: Nephrology Product Name: AT-1501
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not ApplicableUpfront Cash: Not Applicable
Deal Type: Not ApplicableMay 09, 2022
Market Place
Upload your Marketing & Sales content on your company Virtual Booth, click HERE
